TempraMed Moves Into Panama With TEM Distribution Deal to Boost Central American Reach

The latest announcement is out from TempraMed Technologies Ltd. ( (TSE:VIVI) ).

TempraMed Technologies has signed a non-binding letter of intent with Panama-based TEM Consulting International for the distribution of its VIVI temperature-controlled medication devices, marking a strategic entry into the Panamanian market and broader Central American region. Leveraging TEM’s nationwide healthcare logistics network and Panama’s role as a regional gateway, the deal is expected to expand TempraMed’s reach beyond existing partnerships in Korea, Turkey, Israel, and Benelux, initially targeting higher-income, urban, private-pay patients managing diabetes and obesity amid rising prevalence of these conditions.

TEM, a specialist in medical disposables with strong links to Panama’s public and private health systems, will provide access across hospitals, clinics, and pharmacies, supporting scalable rollout of TempraMed’s products. The planned definitive distribution agreement, anticipated within 90 days, underscores TempraMed’s broader Americas and global expansion strategy and could strengthen its competitive positioning in the fast-growing market for temperature-sensitive diabetes and weight-management therapies.

More about TempraMed Technologies Ltd.

TempraMed Technologies Ltd. is a global medical device company focused on innovative, temperature-controlled storage solutions for injectable and other temperature-sensitive medications. Its patented, FDA-registered VIVI thermal insulation devices operate continuously without batteries or external power, targeting patients and healthcare providers who need to maintain medication safety and efficacy in everyday use and travel.

Average Trading Volume: 52,287

Technical Sentiment Signal: Strong Sell

For detailed information about VIVI stock, go to TipRanks’ Stock Analysis page.